<DOC>
	<DOC>NCT01926821</DOC>
	<brief_summary>The impact of sonifilan on the quality of life in patients with cervical cancer during radiation or chemoradiation therapy 1. Primary endpoint : Quality of life 2. Secondary endpoint : complications related to Sonifilan, treatment effect of Sonifilan</brief_summary>
	<brief_title>Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer During Radiation or Chemoradiation Therapy</brief_title>
	<detailed_description>Study design Prospective randomized controlled trial Study period Protocol registration approval date - may/31/2016 Study drug Sonifilan(Sizofiran) Study population 1. Cervical cancer FIGO stage IA2-IVA patients will be participated. 2. Squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma 3. age 20-75 year Treatment Fron the day of radiation therapy started, Sonifilan 20mg, 1amp IM/week for 8weeks Concurrent therapy Chemo &amp; radiation therapy 1. Cisplatin 40mg/m2, day 1, 8, 15, 2, 29, 36 2. External whole pelvic irradiation 3000-3500 cGy / 6 fractions in high dose rate Assessment 1. Pre-study assessment (within 4weeks before participation) a medical history b informed consent c ID number assignment d life quality assessment - fill out EORTC QOQ-C30, CX24, SF-36, FSFI e basic information collect 2. On-study assessment (during study) a complication check b life quality assessment - fill out EORTC QOQ-C30, CX24, SF-36, FSFI 3. Post-study assessment (1week after study finished) a MRI b PAP smear c HPV test d life quality assessment - fill out EORTC QOQ-C30, CX24, SF-36, FSFI 4 Follow-up assessment (every 3 month for 1 year) a Pelvic exam b PAP smear c HPV test d MRI (if needed) e PET (if needed) f life quality assessment - fill out EORTC QOQ-C30, CX24, SF-36, FSFI 93, 6, 12, 24 month after study finished)</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Sizofiran</mesh_term>
	<criteria>Cervical cancer FIGO stage IA2 IVA Histologic type : SCC, Adenocarcinoma, Adenosquamous carcinoma GOG performance status 02 past radiation therapy history Neuroendocrine carcinoma concurrent other cancer uncontrolled medical disease ulcerative disease history current pregnancy and lactation</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>